Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

22.88
-0.4300-1.84%
Post-market: 22.880.00000.00%17:30 EDT
Volume:494.32K
Turnover:11.37M
Market Cap:926.41M
PE:144.96
High:23.37
Open:23.19
Low:22.74
Close:23.31
52wk High:27.64
52wk Low:18.80
Shares:40.49M
Float Shares:36.90M
Volume Ratio:0.54
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1578
EPS(LYR):0.1578
ROE:0.96%
ROA:1.48%
PB:1.34
PE(LYR):144.96

Loading ...

Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist Pressure - Has The Bull Case Changed?

Simply Wall St.
·
Jan 12

Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure

Simply Wall St.
·
Jan 10

Stock Track | Pacira Pharmaceuticals Plummets 13.37% Intraday After Reporting Preliminary FY25 Revenue Results

Stock Track
·
Jan 10

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

Benzinga
·
Jan 10

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Pacira Pharmaceuticals (PCRX) and Beta Bionics, Inc. (BBNX)

TIPRANKS
·
Jan 09

Pacira BioSciences Is Maintained at Buy by Needham

Dow Jones
·
Jan 09

Stocks to Watch: Cemtrex, Olin, Pacira BioSciences, Tilray Brands

Dow Jones
·
Jan 09

Pacira BioSciences Falls After Preliminary Sales Miss Estimates

Dow Jones
·
Jan 09

Pacira 2025 preliminary revenue slightly misses expectations

Reuters
·
Jan 09

Pacira Biosciences FY Revenue USD 726.4 Million VS. Ibes Estimate USD 737.8 Million

THOMSON REUTERS
·
Jan 09

Press Release: Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Dow Jones
·
Jan 09

It’s Earnings Warning Season. How to Profit From Others’ Misery

Dow Jones
·
Jan 01

Update: Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale

MT Newswires Live
·
Jan 01

BRIEF-Doma Perpetual Capital Management Asserts Pacira Biosciences's Board To Pursue Sale Of Company

Reuters
·
Dec 30, 2025

Doma Perpetual Capital Management: Asserts Pacira Biosciences's Board of Directors Should Pursue an Immediate Sale of Company

THOMSON REUTERS
·
Dec 30, 2025

Press Release: DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.

Dow Jones
·
Dec 30, 2025

Pacira BioSciences (PCRX): How the New PROBE Consortium Partnership Shapes Its Current Valuation

Simply Wall St.
·
Dec 26, 2025

Pacira Biosciences Joins PROBE Consortium to Advance Osteoarthritis Research

Reuters
·
Dec 18, 2025

Pacira Biosciences CFO Shawn Cross Reports Disposal of Common Shares

Reuters
·
Dec 12, 2025

Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance

Simply Wall St.
·
Dec 11, 2025